Comment diagnostiquer une dysrégulation des kinases à tyrosine ?

Des tests sanguins et des biopsies peuvent révéler des anomalies dans l'activité des kinases.

Quels marqueurs sont utilisés pour le diagnostic ?

Les marqueurs tumoraux comme le CA 19-9 peuvent indiquer une activité kinase anormale.

Les tests génétiques sont-ils utiles ?

Oui, ils peuvent identifier des mutations dans les gènes codant pour les kinases à tyrosine.

Quels examens d'imagerie sont recommandés ?

L'IRM et le scanner peuvent aider à visualiser les tumeurs associées aux kinases.

Les antécédents familiaux influencent-ils le diagnostic ?

Oui, des antécédents de cancers peuvent augmenter le risque de dysrégulation des kinases.

Quels symptômes sont liés à une suractivité des kinases ?

Fatigue, perte de poids, et douleurs osseuses peuvent indiquer une suractivité des kinases.

Les symptômes varient-ils selon le type de kinase ?

Oui, les symptômes dépendent du type de kinase et de la voie de signalisation affectée.

Y a-t-il des symptômes spécifiques aux cancers ?

Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir.

Les symptômes peuvent-ils être confondus avec d'autres maladies ?

Oui, des symptômes comme la fatigue peuvent être communs à plusieurs maladies.

Comment les symptômes évoluent-ils dans le temps ?

Ils peuvent s'aggraver progressivement, nécessitant une surveillance régulière.

Peut-on prévenir les dysfonctionnements des kinases ?

Une alimentation saine et l'exercice régulier peuvent réduire le risque de cancers.

Les dépistages réguliers sont-ils recommandés ?

Oui, des dépistages peuvent aider à détecter précocement des anomalies liées aux kinases.

Y a-t-il des vaccins préventifs ?

Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des kinases.

Le tabagisme influence-t-il le risque ?

Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers liés aux kinases.

Les facteurs environnementaux jouent-ils un rôle ?

Oui, l'exposition à des substances chimiques peut augmenter le risque de dysfonctionnement des kinases.

Quels traitements ciblent les kinases à tyrosine ?

Les inhibiteurs de kinases, comme l'imatinib, sont utilisés pour traiter certains cancers.

Les traitements sont-ils personnalisés ?

Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases.

Quels effets secondaires des traitements sont courants ?

Fatigue, nausées et éruptions cutanées sont des effets secondaires fréquents.

La radiothérapie est-elle utilisée ?

Oui, la radiothérapie peut être utilisée en complément des traitements ciblés.

Les traitements sont-ils efficaces à long terme ?

L'efficacité varie, mais certains patients peuvent bénéficier d'une rémission prolongée.

Quelles complications peuvent survenir avec les kinases ?

Des complications comme la résistance aux traitements et la progression de la maladie peuvent survenir.

Les complications sont-elles réversibles ?

Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes.

Comment les complications affectent-elles le pronostic ?

Les complications peuvent aggraver le pronostic et réduire les chances de rémission.

Les complications varient-elles selon le type de cancer ?

Oui, les complications peuvent différer selon le type de cancer et la kinase impliquée.

Les complications nécessitent-elles des traitements supplémentaires ?

Oui, des traitements supplémentaires peuvent être nécessaires pour gérer les complications.

Quels sont les principaux facteurs de risque ?

Les antécédents familiaux, le tabagisme et l'exposition à des produits chimiques sont des facteurs de risque.

L'âge influence-t-il le risque de dysfonctionnement des kinases ?

Oui, le risque augmente généralement avec l'âge, surtout pour certains cancers.

Le mode de vie joue-t-il un rôle ?

Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque.

Les infections peuvent-elles être un facteur de risque ?

Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque.

Y a-t-il des facteurs génétiques impliqués ?

Oui, des mutations génétiques héréditaires peuvent prédisposer à des dysfonctionnements des kinases.

Protein-tyrosine kinases - Informations médicales vérifiées

Targeted lateral pelvic lymph node excision in the setting of total neoadjuvant therapy for rectal cancer.

03 2023

DOI: 10.1111/ans.18149 PMID: 36398435

Targeted lateral pelvic node dissection in the era of total neoadjuvant therapy....

Humans Neoadjuvant Therapy Lymph Node Excision Lymph Nodes Pelvis +3 autres

Prone position thoracoscopic-assisted total mesoesophageal excision: initial experiences and benefits of lymph node dissection.

03 2023

DOI: 10.1007/s00464-022-09704-x PMID: 36289085

Total mesoesophageal excision (TME) is a promising procedure. Prone position thoracoscopic-assisted TME might be a good choice, even without robust evidence yet. Therefore, it is necessary to explore ... We retrospectively analyzed the short-term outcomes regarding intraoperative unplanned events, postoperative complications, and lymphadenectomy in 61 patients who underwent prone position thoracoscopi... Of these sixty-one patients, there were 10, 24 and 27 cases of tumor in the upper, middle, and lower thoracic, respectively. Although there were five cases of unplanned events during surgery, no conve... The prone position thoracoscopic-assisted TME is a safe procedure that is more conducive to thoracic lymph node dissection, especially for middle and lower mediastinum....

Humans Prone Position Retrospective Studies Esophageal Neoplasms Lymph Node Excision +4 autres

Efficacy of octreotide to reduce lymphorrhea and prevent lymphocele after pelvic lymph node excision in gynecological malignancies.

Aug 2023

DOI: 10.1111/jog.15702 PMID: 37254619

To study the efficacy of octreotide to reduce lymphorrhea and prevent lymphocele after pelvic lymph node excision in gynecological malignancies.... Patients with more than 200 mL of lymph drained per day until postoperative day 3 after pelvic lymph node excision were enrolled. Of the 75 patients, 36 were managed by conservative methods without th... The total and mean daily amount of lymph produced per patient was significantly lower in the octreotide-treated group than in the untreated group. The duration of drain placement was shorter in the oc... The injection of octreotide is effective to reduce lymphorrhea and prevent lymphocele after pelvic lymph node excision in gynecological malignancies....

Female Humans Lymphocele Octreotide Genital Neoplasms, Female +2 autres

Subcostal lymph nodes: An unusual sentinel lymph node basin in cutaneous melanoma.

Dec 2022

DOI: 10.1002/jso.27022 PMID: 35870116

Lymphatic drainage from subcostal nodes, along the costal groove, have not previously been characterized as sites for melanoma drainage and metastasis. This study reports a series of patients with sub... Patients who presented to our institution between 2005 and 2020 with documented cutaneous melanoma and sentinel lymph node biopsy of a subcostal node (sentinel = S), or metastases to subcostal nodes l... Six patients had subcostal sentinel nodes (SNs). Primary sites included the posterior trunk and lateral chest wall. Subcostal nodes were found under ribs 10-12. Subcostal SNs had at least one dimensio... Melanoma can metastasize to subcostal lymph nodes and be found at the time of SN biopsy or identified at recurrence. These small nodes are fed by lymphatic channels that run in the neurovascular bundl...

Humans Melanoma Skin Neoplasms Sentinel Lymph Node Lymphatic Metastasis +5 autres

Lymph Node Positivity of Axillary Reverse Mapping Lymph Nodes at the Time of Axillary Lymph Node Dissection: Two-Site Prospective Trial.

Oct 2023

DOI: 10.1245/s10434-023-13883-9 PMID: 37466868

Axillary reverse mapping (ARM) was introduced in 2007 to identify and selectively preserve upper-extremity lymphatics during axillary lymph node surgery to decrease the risk of lymphedema. The patient... Patients undergoing ALND with or without immediate lymphatic reconstruction (ILR) were enrolled in a prospective trial at two institutional sites between April 2018 and Decemeber 2022. This report ana... The inclusion criteria were met by 139 patients, who made up the study population (133 with breast cancer and 6 with other disease). Of the breast cancer patients, 99.2% were female, 35.3% (47/133) we... In the contemporary patient population undergoing ALND, the positivity rate of the ARM LN was relatively high, suggesting that leaving ARM LNs in patients undergoing ALND may not be oncologically safe...

Female Humans Male Axilla Breast Neoplasms +5 autres

Sentinel Lymph Node Identification in Post Neoadjuvant Chemotherapy Breast Cancer Patients Undergoing Surgical Excision Using Lymphosonography.

Jul 2023

DOI: 10.1002/jum.16164 PMID: 36591785

This study evaluated the efficacy of lymphosonography in the identification of sentinel lymph nodes (SLNs) in post neoadjuvant chemotherapy patients with breast cancer scheduled to undergo surgical ex... Seventy-nine subjects scheduled for breast cancer surgery with SLN excision completed this IRB-approved study, out of which 18 (23%) underwent neoadjuvant chemotherapy before surgery. Subjects underwe... Seventy-two SLNs were surgically excised from 18 subjects, 29 were positive for blue dye, 63 were positive for radioactive tracer and 57 were positive for Sonazoid. Comparison with blue dye showed tha... Lymphosonography achieved similar accuracy as radioactive tracer and higher accuracy than blue dye for identifying SLNs. The 15 SLNs positive for malignancy were all identified by lymphosonography....

Humans Female Sentinel Lymph Node Breast Neoplasms Sentinel Lymph Node Biopsy +6 autres

Prediction of nonsentinel lymph node metastasis in acral melanoma with positive sentinel lymph nodes.

Dec 2023

DOI: 10.1002/jso.27438 PMID: 37689989

Metastasis in a nonsentinel lymph node (non-SLN) is an unfavorable independent prognostic factor in cutaneous melanoma (CM). Recent data did suggest potential value of completion lymph node dissection... This retrospective study enrolled 656 cases of melanoma who underwent sentinel lymph node biopsy at Fudan University Shanghai Cancer Center from 2009 to 2017. We identified 81 SLN + AM patients who un... Ulceration, Clark level, number of deposits in the SLN (NumDep) and maximum size of deposits (MaxSize) are independent risk factors associated with non-SLN metastases. We developed a scoring system th... A scoring system that included ulceration, Clark level, MaxSize, and NumDep is reliable and effective for predicting non-SLN metastasis in SLN-positive AM....

Humans Melanoma Skin Neoplasms Lymphatic Metastasis Sentinel Lymph Node +7 autres

Prognostic Value of Lymph Node Yield, Lymph Node Density, and pN in Oral Cancer.

08 2023

DOI: 10.1177/01945998221123927 PMID: 36066971

To investigate thresholds for lymph node yield (LNY), lymph node density (LND), and pN in patients with oral squamous cell carcinoma in relation to previous findings in the literature.... Retrospective register-based study.... Copenhagen Oral Cavity Squamous Cell Carcinoma database.... Appropriate thresholds for LNY, LND, and pN were determined by areas under the curve and subsequently subjected to multivariate analysis. Five-year overall survival and 3-year recurrence-free survival... In total, 413 patients diagnosed with oral squamous cell carcinoma were included. In the pN0 cohort, no superior/prognostic LNY cutoff values were detected. In the pN+ cohort, areas under the curve de... Increased nodal yield, decreased LND, and decreasing number of pN were associated with significantly improved survival outcomes. LNY might serve as a prognosticator of survival as well as a surgical q...

Humans Prognosis Carcinoma, Squamous Cell Retrospective Studies Mouth Neoplasms +5 autres

Effect of inguinal lymph node dissection in lymph node negative patients with squamous cell carcinoma of the penis.

Jan 2023

DOI: 10.1007/s00345-022-04184-z PMID: 36239810

The survival benefit of inguinal lymph node dissection (ILND) vs no ILND in patients with squamous cell carcinoma of the penis (SCCP) and the absence of lymph node invasion is unclear. We addressed th... We identified lymph node negative SCCP patients who either underwent ILND (pN0) or clinical examination only (cN0). We tested for the effect of ILND vs no ILND on cancer-specific mortality (CSM) in Ka... Of 2520 SCCP patients, 369 (15%) underwent ILND (pN0) vs 2151 (85%) did not (cN0). The pN0 vs cN0 distribution according to pT stages was as follows: 80 (7%) vs 1092 (93%) in pT1b, and 289 (21%) vs 10... In pT2-3 stage SCCP, a significantly lower CSM was recorded in lymph node negative patients treated with ILND than in their clinical lymph node negative counterparts who did not undergo ILND....

Male Humans Lymph Node Excision Lymph Nodes Proportional Hazards Models +3 autres

Predictive Value of Jugulo-omohyoid Lymph Nodes in Lateral Lymph Node Metastasis of Papillary Thyroid Cancer.

21 May 2024

DOI: 10.1186/s12902-024-01576-7 PMID: 38773428

Jugulo-omohyoid lymph nodes (JOHLN) metastasis has proven to be associated with lateral lymph node metastasis (LLNM). This study aimed to reveal the clinical features and evaluate the predictive value... A total of 550 patients pathologically diagnosed with PTC between October 2015 and January 2020, all of whom underwent thyroidectomy and lateral lymph node dissection, were included in this study.... Thyroiditis, tumor location, tumor size, extra-thyroidal extension, extra-nodal extension, central lymph node metastasis (CLNM), and LLMM were associated with JOHLN. Male, upper lobe tumor, multifocal... JOLHN metastasis could be a clinically sensitive predictor of further LLM. A high-performance nomogram was established, which can provide an individual risk assessment of LNM and guide treatment decis...

Humans Male Lymphatic Metastasis Female Thyroid Cancer, Papillary +12 autres

Protein-tyrosine kinases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Questions fréquentes et termes MeSH associés

Diagnostic 5

Symptômes 5

Prévention 5

Traitements 5

Complications 5

Facteurs de risque 5

Contenu validé par Dr Olivier Menir

Sous-catégories

Agammaglobulinaemia tyrosine kinase

Focal adhesion protein-tyrosine kinases

Janus kinases

Mitogen-Activated Protein Kinase Kinases

Syk kinase

src-Family kinases

ZAP-70 Protein-tyrosine kinase

Janus kinase 1

Janus kinase 3

TYK2 Kinase

MAP Kinase Kinase 1

MAP Kinase Kinase 2

MAP Kinase Kinase 3

MAP Kinase Kinase 4

MAP Kinase Kinase 5

MAP Kinase Kinase 6

MAP Kinase Kinase 7

CSK tyrosine-protein kinase

Auteurs principaux

Sources (7934 au total)